Expression and immunoprotective effect of a Toxoplasma gondii four-antigen fusion protein

doi:10.12140/j.issn.1000-7423.2025.04.016

Abstract

Abstract:

Objective To investigate the immunoprotective effect of a four-antigen fusion protein vaccine (referred to as 4 ×) composed of Toxoplasma gondii rhoptry protein 18 (ROP18), centrin family protein TGME49_237490, oocyst wall-specific protein ortholog TGME49_268230, and microneme protein 13 (MIC13). Methods The 4 × target gene was amplified using PCR assay, and recombinant plasmids were constructed and characterized. The successfully constructed plasmids were transformed into Escherichia coli BL21 competent cells for induced expression and affinity purification of the target protein, and the expression of the target protein was determined using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting. Thirty-six female BALB/c mice were randomly divided into an immunization group and a control group, of 18 mice in each group. Mice in the immunization group were injected with 4 × protein and Freund’s adjuvant, and animals in the control group were administered with phosphate-buffered saline and Freund’s adjuvant. Immunizations were administered three times at two-week intervals. Blood samples were collected from the orbital sinus 0, 2, 4, 6 weeks following immunization, and serum samples were isolated. The levels of serum IgG antibodies were measured using ELISA. In the final detection, the levels of IgG antibody subtypes were also assessed. Two weeks after the final immunization, ten mice from each group were sacrificed, and spleens were aseptically harvested to prepare splenocyte suspensions. Splenocyte suspensions from five mice were used to measure cell proliferation using the CCK8 assay, while those from the other five mice were used for analysis of cytokine levels using flow cytometry. Mouse peripheral blood was sampled two weeks following final immunization, and proportions of mouse T cell subsets were detected using flow cytometry in five mice from each group. Eight mice were sampled from each group two weeks following final immunization and challenged intraperitoneally with 100 tachyzoites of the T. gondii RH strain. Then, the burdens of T. gondii in organs of 3 mice were examined using real-time quantitative fluorescence PCR (qPCR) assay, and the survival of other 5 mice were monitored daily and survival curves were plotted, statistical analysis was performed using GraphPad Prism 8 software. Results The PCR amplification product of the 4 × gene was 3 576 bp, which was consistent with the expected size. Recombinant plasmids showed expected band sizes upon characterization with PCR assay and enzymatic digestion. The target protein was successfully expressed and purified, with prominent bands observed at M_r 110 000 by both SDS-PAGE and Western blotting. ELISA results showed that the IgG antibody levels (A₄₅₀ values) in the immunized group at weeks 0, 2, 4, and 6 post-immunization were 0.079 ± 0.004, 0.759 ± 0.179, 1.670 ± 0.243, and 2.461 ± 0.056, respectively. The corresponding values for the control group were 0.080 ± 0.006, 0.067 ± 0.009, 0.080 ± 0.014, and 0.076 ± 0.011, respectively. Except for week 0 (t = 0.05, P > 0.05), the IgG levels in the immunized group were significantly higher than those in the control group (t = 9.88, 23.33, 34.66; all P < 0.05). At week 6 post-immunization, the absorbance values of IgG1 and IgG2a antibodies were 3.202 ± 0.401 and 3.725 ± 0.066 in the immunization group and 0.082 ± 0.003 and 0.059 ± 0.017 in the control group (t = 13.73, 96.83; both P < 0.05), respectively. Flow cytometry detected that the levels of IFN-γ, IL-2, IL-12, IL-4, and IL-10 were (4 998.52 ± 2 131.24), (5.76 ± 1.02), (1.38 ± 0.86), (28.83 ± 1.64), and (3 376.57 ± 218.48) pg/ml in the immunization group and (8.90 ± 0.17), (3.05 ± 0.50), (0.06 ± 0.13), (11.18 ± 1.58), (13.87 ± 3.55) pg/ml in the control group (t = 4.89, 4.61, 3.06, 15.93, 30.30; all P < 0.05), respectively, and the proliferation level of splenocytes was 3.286 ± 0.552 in the immunization group and 1.251 ± 0.157 in the control group (t = 9.15, P < 0.05). The proportions of CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells were (31.15 ± 2.83)% and (18.06 ± 2.82)% in the immunization group and (26.82 ± 1.17)% and (9.33 ± 1.22)% in the control group (t = 3.16, 6.36; both P < 0.05), respectively. RT-qPCR assay detected that parasite burdens were (206.7 ± 16.0), (100.2 ± 15.4), and (7.1 ± 2.0) fg/mg in the mouse liver, spleen, and lungs in the immunization mice, and (20 086.0 ± 1 310.0), (26 254.0 ± 9 658.0) and (5 300.0 ± 741.2) fg/mg in the control group (t = 26.29, 4.69, 12.37; all P < 0.05). All mice in the control group died within 8 days following challenge, in the immunized group, only one mouse survived throughout the 30 d observation period, with a significantly prolonged survival time (χ² = 7.47, P < 0.05). Conclusion The four-antigen fusion protein vaccine may induce effective humoral and cellular immune responses in mice and present a significant protective effect against acute T. gondii infection.

Key words: Toxoplasma gondii, Four-antigen fusion protein, Protein vaccine, Immunoprotection

CLC Number:

R382.5

WU Qinli, NI Ze, DING Haojie, DING Jianzu, ZHENG Bin, ZHUO Xunhui, LU Shaohong. Expression and immunoprotective effect of a Toxoplasma gondii four-antigen fusion protein[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2025, 43(4): 555-561.

Figures/Tables 4

Fig. 1

Fig. 2

Fig. 3

Fig. 4

References 30

[1]	Hashizaki E, Sasai M, Okuzaki D, et al. Toxoplasma IWS1 determines fitness in interferon-γ-activated host cells and mice by indirectly regulating ROP18 mRNA expression[J]. mBio, 2023, 14(1): e0325622.
[2]	Flegr J, Prandota J, Sovi?ková M, et al. Toxoplasmosis: A global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries[J]. PLoS One, 2014, 9(3): e90203.
[3]	Molan A, Nosaka K, Hunter M, et al. Global status of Toxoplasma gondii infection: Systematic review and prevalence snapshots[J]. Trop Biomed, 2019, 36(4): 898-925.
[4]	Pan M, Lyu CC, Zhao JL, et al. Sixty years (1957-2017) of research on toxoplasmosis in China-an overview[J]. Front Microbiol, 2017, 8: 1825.
[5]	刘平, 刘俐君, 唐斌, 等. 我国人畜间弓形虫感染状况及流行特征[J]. 中国动物检疫, 2025, 42(3): 1-6.
	Liu P, Liu LJ, Tang B, et al. Toxoplasma gondii infection in humans and animals and its epidemiological characteristics in China[J]. China Anim Health Insp, 2025, 42(3): 1-6. (in Chinese)
[6]	丁金龙, 钦博, 吴云路, 等. 弓形虫感染对贫血孕妇妊娠结局的影响及免疫指标相关性研究[J]. 中国地方病防治, 2025, 40(3): 223-224.
	Ding JL, Qin B, Wu YL, et al. Study on the influence of Toxoplasma gondii infection on pregnancy outcome of Anemia pregnant women and the correlation of immune indexes[J]. Chin J Control Endem Dis, 2025, 40(3): 223-224. (in Chinese)
[7]	Zhang NZ, Wang M, Xu Y, et al. Recent advances in developing vaccines against Toxoplasma gondii: An update[J]. Expert Rev Vaccines, 2015, 14(12): 1609-1621.
[8]	Liu F, Wu MM, Wang J, et al. Protective effect against toxoplasmosis in BALB/c mice vaccinated with recombinant Toxoplasma gondii MIF, CDPK3, and 14-3-3 protein cocktail vaccine[J]. Front Immunol, 2021, 12: 755792.
[9]	Li D, Han M, Cao YH, et al. Protective effect against toxoplasmosis in BALB/C mice vaccinated with recombinant Toxoplasma gondii CDPK3, GRA35, and ROP46 protein cocktail vaccine[J]. Vaccine, 2024, 42(6): 1342-1351.
[10]	Pinzan CF, Sardinha-Silva A, Almeida F, et al. Vaccination with recombinant microneme proteins confers protection against experimental toxoplasmosis in mice[J]. PLoS One, 2015, 10(11): e0143087.
[11]	Ye S, Xia NB, Zhao PF, et al. Micronemal protein 13 contributes to the optimal growth of Toxoplasma gondii under stress conditions[J]. Parasitol Res, 2019, 118(3): 935-944.
[12]	Yuan ZG, Ren D, Zhou DH, et al. Evaluation of protective effect of pVAX-TgMIC13 plasmid against acute and chronic Toxoplasma gondii infection in a murine model[J]. Vaccine, 2013, 31(31): 3135-3139.
[13]	Zhu YC, He Y, Liu JF, et al. Adjuvantic cytokine IL-33 improves the protective immunity of cocktailed DNA vaccine of ROP5 and ROP18 against Toxoplasma gondii infection in mice[J]. Parasite, 2020, 27: 26.
[14]	Ramakrishnan C, Maier S, Walker RA, et al. An experimental genetically attenuated live vaccine to prevent transmission of Toxoplasma gondii by cats[J]. Sci Rep, 2019, 9(1): 1474.
[15]	Chalmin F, Humblin E, Ghiringhelli F, et al. Transcriptional programs underlying Cd4 T cell differentiation and functions[J]. Int Rev Cell Mol Biol, 2018, 341: 1-61.
[16]	St Paul M, Ohashi PS. The roles of CD8⁺ T cell subsets in antitumor immunity[J]. Trends Cell Biol, 2020, 30(9): 695-704.
[17]	Tsitsiklis A, Bangs DJ, Robey EA. CD8⁺ T cell responses to Toxoplasma gondii: Lessons from a successful parasite[J]. Trends Parasitol, 2019, 35(11): 887-898.
[18]	Grzybowski MM, Dziadek B, Gatkowska JM, et al. Towards vaccine against toxoplasmosis: Evaluation of the immunogenic and protective activity of recombinant ROP5 and ROP18 Toxoplasma gondii proteins[J]. Parasitol Res, 2015, 114(12): 4553-4563.
[19]	Denkers EY, Gazzinelli RT. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection[J]. Clin Microbiol Rev, 1998, 11(4): 569-588.
[20]	Trinchieri G, Peritt D, Gerosa F. Acute induction and priming for cytokine production in lymphocytes[J]. Cytokine Growth Factor Rev, 1996, 7(2): 123-132.
[21]	Dupont CD, Christian DA, Hunter CA. Immune response and immunopathology during toxoplasmosis[J]. Semin Immunopathol, 2012, 34(6): 793-813.
[22]	Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: From molecular mechanisms to human therapy[J]. Nat Rev Immunol, 2018, 18(10): 648-659.
[23]	Zhao YL, Wilson D, Matthews S, et al. Rapid elimination of Toxoplasma gondii by gamma interferon-primed mouse macrophages is independent of CD40 signaling[J]. Infect Immun, 2007, 75(10): 4799-4803.
[24]	Mordue DG, Monroy F, Regina ML, et al. Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines[J]. J Immunol, 2001, 167(8): 4574-4584.
[25]	Kidd P. Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease[J]. Altern Med Rev, 2003, 8(3): 223-246.
[26]	Suzuki Y, Sher A, Yap G, et al. IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with Toxoplasma gondii[J]. J Immunol, 2000, 164(10): 5375-5382.
[27]	Sauer A, Villard O, Creuzot-Garcher C, et al. Intraocular levels of interleukin 17A (IL-17A) and IL-10 as respective determinant markers of toxoplasmosis and viral uveitis[J]. Clin Vaccine Immunol, 2015, 22(1): 72-78.
[28]	Tonkonogy SL, McKenzie DT, Swain SL. Regulation of isotype production by IL-4 and IL-5. Effects of lymphokines on Ig production depend on the state of activation of the responding B cells[J]. J Immunol, 1989, 142(12): 4351-4360.
[29]	Billiau A, Matthys P. Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases[J]. J Leukoc Biol, 2001, 70(6): 849-860.
[30]	O’Hagan DT, Fox CB. New generation adjuvants: From empiricism to rational design[J]. Vaccine, 2015, 33(Suppl 2): B14-B20.